Mumbai, January 30, 2025 – Dr. Lal PathLabs Limited has announced its unaudited financial results for the quarter and nine months ended December 31, 2024. The Board also approved the third interim dividend and granted in-principle approval for the voluntary liquidation of its wholly owned subsidiary, Suburban Diagnostics (India) Pvt. Ltd.
Key Financial Highlights (Consolidated)
(Figures in ₹ million, except per share data)| Particulars | Q3 FY25 | Q2 FY25 | Q3 FY24 | 9M FY25 | 9M FY24 | FY24 (Audited) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 5,987 | 6,604 | 5,389 | 18,568 | 16,812 | 22,266 |
| Total Income | 6,218 | 6,821 | 5,572 | 19,164 | 17,320 | 22,994 |
| Profit Before Tax (PBT) | 1,383 | 1,831 | 1,159 | 4,713 | 3,156 | 5,055 |
| Net Profit | 981 | 1,308 | 822 | 3,367 | 2,765 | 3,613 |
| EPS (Basic, ₹) | 11.69 | 15.52 | 9.77 | 39.91 | 32.88 | 43.05 |
Segment Performance
The company has not provided a segmented breakdown, as it operates as a single unit under Indian Accounting Standard (Ind AS) 108.Key Corporate Developments
1. Declaration of ₹6 Interim Dividend
The Board has approved a third interim dividend of ₹6 per share (60% on face value of ₹10 each) for FY25. The record date for eligibility is February 5, 2025, with distribution expected within 30 days.2. Voluntary Liquidation of Suburban Diagnostics
The company has granted in-principle approval for the voluntary liquidation of its wholly owned subsidiary, Suburban Diagnostics (India) Pvt. Ltd., aiming for operational consolidation. As of March 31, 2024, Suburban contributed ₹164.03 crore in revenue and ₹126.62 crore in net worth. The process is subject to regulatory approvals.3. Postal Ballot for Director Commission
A postal ballot will seek shareholder approval to pay commissions to non-executive and independent directors.4. Regulatory and Governance Updates
- Amendments to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) were approved.
Management Commentary
Despite seasonal fluctuations, the company’s leadership emphasized steady growth in revenues and profits. The decision to liquidate Suburban Diagnostics aligns with the long-term goal of streamlining operations and optimizing cost efficiencies. The company remains committed to delivering value through strategic initiatives.Outlook
- The company remains optimistic about demand recovery and expects more substantial growth in diagnostic services in the coming quarters.
- Cost optimizations from Suburban’s integration are likely to improve margins in FY26.
- Investor focus will be on profitability improvement and market share expansion in domestic and international markets.
Conclusion
Dr. Lal PathLabs has maintained strong growth momentum, with improved YoY revenue and profitability. The dividend declaration underscores its healthy financial position, while the strategic exit from Suburban Diagnostics aims to enhance operational efficiency.Investors will closely watch Q4 trends for signs of sustained earnings improvement and strategic execution.